# Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.

> **NCT01451775** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT01451775
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451775, "Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01451775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*